ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Varmus: Why are scientific societies obstructing public access to research results?

May 20, 2005

Deals & Collaborations: UAB To Evaluate Firm’s Prostate Cancer Treatment

June 1, 2001

Phase III Xilonix Study Halted Following Unscheduled Analysis

September 26, 2014

Klausner Unveils New NCI Structure, Aims To Change Institute’s “Ethos”

August 11, 1995

Chemoprevention Concept Approved By DCPC Bard Uses Biological Markers To Assess Risk Modulation

September 27, 1985

AIDS Cachexia Drug Stabilizes Body Weight, Muscle Mass

March 29, 2013